Absci reports Q2 2026 results, positive ABS-201 Phase 1 data, $100M raise with Lilly
Absci says its hair-loss antibody was well tolerated in early dosing, adds $40 million from Eli Lilly, and now expects cash to last into second half of 2028.
SEC filing